Share-Based Compensation (Tables)

3 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the three months ended September 30, 2019 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2019		5.5		$	24.45
Options granted		—		$	—
Less:
Options exercised		(0.4	)	$	22.87
Options canceled or expired		(0.1	)	$	30.00
Options outstanding at September 30, 2019		5.0		$	24.39
Options exercisable at September 30, 2019		5.0		$	24.39

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the three months ended September 30, 2019 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2019		2.4		$	37.70
RSUs granted		1.2		$	29.89
Less:
RSUs vested		(0.8	)	$	36.00
RSUs canceled		(0.1	)	$	46.00
RSUs outstanding at September 30, 2019		2.7		$	34.71

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended
	September 30,
	2019		2018
Cost of molecular diagnostic testing	$	0.2	$	0.2
Cost of pharmaceutical and clinical services		0.1		0.1
Research and development expense		1.5		1.2
Selling, general, and administrative expense		7.0		6.2
Total share-based compensation expense	$	8.8	$	7.7